Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eltanexor + abiraterone + corticosteroids
- Development stage
- Phase 2
- Lead developer
- Karyopharm Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Eltanexor + abiraterone + corticosteroids is an investigational combination regimen studied primarily in metastatic castration-resistant prostate cancer (mCRPC). Eltanexor is a second-generation, orally bioavailable selective inhibitor of nuclear export (SINE) compound that blocks exportin-1 (XPO1)-mediated nuclear export, leading to restoration of tumor suppressor protein function. Abiraterone is a selective, irreversible inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase), causing androgen depletion. Corticosteroids, typically prednisone or prednisolone, mitigate the side effects of abiraterone-induced mineralocorticoid excess and may reduce constitutional adverse events from eltanexor. This combination is given orally, and has been studied in heavily pre-treated mCRPC patient cohorts. Initial studies suggest that corticosteroids may improve the tolerability of the regimen, and the combination warrants further investigation. The drugs act through synergistic antineoplastic and hormonal mechanisms targeting prostate cancer with resistance to conventional therapies[1][2][3][4].
- Other names
- eltanexor + abiraterone + corticosteroids
02
Targets
AR (Adrenergic receptors)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)GR (Glucocorticoid receptor)XPO1 (Exportin-1)
Beyond the preview
Go deeper on eltanexor + abiraterone + corticosteroids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eltanexor + abiraterone + corticosteroids.